ABSTRACT:Heracleum platytaenium is an edible herb and strongly aromatic plant that is endemic to Turkey. Although, a number of studies have been conducted on the components and composition of essential oils of the different parts of this species, its antioxidant, antiproliferative and /or cytotoxic proporties have never been explored. The present study aimed to evaluate total phenolic content (TPC), total flavonoid content (TFC), the antioxidant activity and anticancer properties of the methanolic extracts of H. platytaenium. The results showed that the total phenolic and flavonoid contents were found to be higher in the methanolic extracts from the flowers of the plant. The methanolic flower extract of H. platytaenium scavenged about 86% and stem extract of H. platytaenium scavenged about 83% of free DPPH radicals. The best inhibitory profile for GST was observed with the methanolic extract of the plant from flowers. In addition, the methanol extract of H. platytaenium from the stem increased GPx activity with the 1.25 mg/mg plant extract. The maximum dose of the flower and stem extracts of the plant inhibited 10 % and 8% CAT activity. Then, MTT assay was used for the study of the cytotoxic effect of the plant extracts. Both methanolic flower and stem extract of H. platytaenium showed moderate anticancer effect on T47-D cell lines, but no cytotoxic effect was observed on MDA-MB-231 cells. In conclusion, methanolic extracts of H. platytaenium flower and stem showed apparent antioxidant and cytotoxic effects leading the way for their potential use as food additives to help to fight against the growth and spreading of cancerous cells. However, for a definitive conclusion, further studies on other cell lines as well as animal models and subsequent clinical studies are warranted.
SUMMARYBreast cancer is the most commonly diagnosed type of cancer among females worldwide. It is also the leading cause of female cancer-related death in developing countries. Though novel biomarkers and new strategies for diagnosis, monitoring course of disease, and treatment of breast cancer have been found, these methods are invasive, costly, labor-intensive, and inadequate to fully gauge treatment response and disease recurrence. Therefore, novel biomarkers with greater sensitivity and specificity, and which are easy to perform are needed in breast cancer oncology. There is growing interest in the potential use of circulating tumor cells and circulating tumor deoxyribonucleic acid fragments in liquid biopsy as non-invasive biopsy materials for early detection of breast cancer, monitoring disease progression, and understanding reasons for treatment resistance. This review is a discussion of current status of utilization of these liquid biopsy materials in breast oncology.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.